The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Christopher Winston Uhde - SEB, Research Division - Analyst
: So my first one is on Efan alfa and the EMA process, you previously indicated we should expect a -- we could probably expect a pretty quick process
given how well the mechanism is understood and how clear the data is and so on.
Does that mean that there is scope to for the EMA to give you the 180-day questions ahead of the 180-day time? Or should we still expect 180 days
to be in place? And then, I think so does the financing increase or decrease the odds or does it impact the odds of you monetizing the nirsevimab
royalty stream and then especially in the short term?
And then thirdly, so Vonjo, coming back to the ramp and potential. So obviously, any sort of uptake? There's the usual work to be done to get
physicians aware and patients aware and whatnot. But beyond that, just looking at the projections, this could -- this has the potential to be an
absolutely massive drug for you guys. What do you need to overcome to get as many patients on to therapy within the label population alone to
start with?
Question: Alistair David Campbell - RBC Capital Markets, Research Division - Analyst
: Got 2 questions, if I may. The first one is on Doptelet just really want to be clear on this. Obviously, a very large China sales number in Q2. But if I
were to assume no more China sales this year -- second half of this year or next year, but the underlying run rate for Doptelet ex China, I'm probably
getting to a number that looks like broadly year-on-year, you've been flat for Doptelet. Is that reasonable? Or do you think you can do better than
that?
And then the second question is on ALTUVIIIO. A couple of weeks ago, Sam, if you were talking about the launch in the U.S. and saying, it's going
ahead of expectations. They're taking about 10% of patients from Hemlibra. So quite an optimistic outlook from them, and I'm sure we'll hear more
from them next week. Just how good a proxy do you think the U.S. launch for ALTUVIIIO where is when we think about your launch in Europe albeit
it will be slower in sort of market by market.
Question: Alistair David Campbell - RBC Capital Markets, Research Division - Analyst
: The ALTUVIIIO launch?
|
